60 Degrees Pharmaceuticals, Inc. Warrant

60 Degrees Pharmaceuticals reported Q3 2025 financial results with 223% net product revenue increase, but experienced a gross loss due to inventory write-off. The company is exploring new treatment indications for tafenoquine, including potential treatments for canine babesiosis and chronic babesiosis.

U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.